

Title (en)
A NEW ANALGESIC, ANTI-INFLAMMATORY AND WOUND HEALING AGENT

Title (de)
NEUER ANALGETISCHER, ANTIINFLAMMATORISCHER UND WUNDHEILENDER WIRKSTOFF

Title (fr)
NOUVEL AGENT ANALGESIQUE, ANTI-INFLAMMATOIRE ET CICATRISANT

Publication
EP 1102578 A4 20050518 (EN)

Application
EP 99942002 A 19990803

Priority
• US 9917642 W 19990803
• US 9509098 P 19980803

Abstract (en)
[origin: WO0007566A1] Composition and formulations comprise a brain, heart, lung and/or vascular system protecting amount of a first agent such as folic acid, pharmaceutically acceptable salts thereof or mixtures thereof and a carrier, and optionally a second agent such as analgesics, heart medicines, anti-inflammatory agents, soporifics, muscle relaxants, anti-pyretic agents, anti-fibrillation agents, heart, brain, lung and vascular drugs, anxiolytic agents, mood controlling agents, and many others. The products are suitable for the treatment of previous mood disorders, symptoms and sequelae of menopause, pain, inflammation, insomnia, restless sleep, trauma, surgery, burns, conditions and diseases which bring these symptoms, ischemia, Supra Ventricular Tachycardia (SVT), heart conditions, and heart failure, Acute Respiratory Distress Syndrome (ARDS), COPS, allergic rhinitis, and other conditions, and for reducing the number and severity of heart attacks, as well as for alleviating other diseases associated with the heart, and more generally, for the assessment of heart function. An edible product is prepared with the agent of the invention.

IPC 1-7
A61K 31/519; **A61K 45/06**; **A61P 3/00**; **A61P 9/00**; **A61P 13/12**; **A61P 23/00**; **A61P 25/00**; **A61P 29/00**

IPC 8 full level
A61K 31/519 (2006.01); **A61K 45/06** (2006.01)

CPC (source: EP)
A61K 31/519 (2013.01); **A61K 45/06** (2013.01); **A61P 3/00** (2017.12); **A61P 9/00** (2017.12); **A61P 13/12** (2017.12); **A61P 23/00** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12)

C-Set (source: EP)
A61K 31/519 + **A61K 2300/00**

Citation (search report)
• [E] WO 0040172 A1 20000713 - NYCE JONATHAN W [US]
• [PX] EP 0898965 A2 19990303 - EPROVA AG [CH]
• [X] WO 9819690 A1 19980514 - BRISTOL MYERS SQUIBB CO [US]
• [X] EP 0382019 A1 19900816 - BIORESEARCH SPA [IT]
• [X] US 5118505 A 19920602 - KOELTRINGER PETER [AT]
• [Y] KELLY G S: "Folates: supplemental forms and therapeutic applications.", ALTERNATIVE MEDICINE REVIEW : A JOURNAL OF CLINICAL THERAPEUTIC. JUN 1998, vol. 3, no. 3, June 1998 (1998-06-01), pages 208 - 220, XP009045488, ISSN: 1089-5159
• [Y] CASTRO ALONSO F J ET AL: "Treatment of ocular toxoplasmosis", FARMACIA CLINICA, vol. 15, no. 2, March 1998 (1998-03-01), pages 119 - 124, XP009045489, ISSN: 0212-6583
• [Y] KEPKA L ET AL: "Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure.", LEUKEMIA & LYMPHOMA. MAR 1998, vol. 29, no. 1-2, March 1998 (1998-03-01), pages 205 - 209, XP009045482, ISSN: 1042-8194
• [A] DAVIES ET AL: "FACILITATORY AND DIRECT EXCITATORY EFFECTS OF FOLATE AND FOLINATE ON SINGLE NEURONES OF CAT CEREBRAL CORTEX", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 13, no. 22, 1 July 1973 (1973-07-01), pages 1667 - 1668, XP001078712, ISSN: 0006-2952
• See references of WO 0007566A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0007566 A1 20000217; AU 5547099 A 20000228; CA 2348637 A1 20000217; CN 1311665 A 20010905; EP 1102578 A1 20010530; EP 1102578 A4 20050518; MX PA01000973 A 20020604

DOCDB simple family (application)
US 9917642 W 19990803; AU 5547099 A 19990803; CA 2348637 A 19990803; CN 99809298 A 19990803; EP 99942002 A 19990803; MX PA01000973 A 19990803